BR0215218A - Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo - Google Patents

Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo

Info

Publication number
BR0215218A
BR0215218A BR0215218-5A BR0215218A BR0215218A BR 0215218 A BR0215218 A BR 0215218A BR 0215218 A BR0215218 A BR 0215218A BR 0215218 A BR0215218 A BR 0215218A
Authority
BR
Brazil
Prior art keywords
individual
composition
inhibiting
methods
liquid aqueous
Prior art date
Application number
BR0215218-5A
Other languages
English (en)
Inventor
Birthe Lykkegaard Hansen
Michael Bech Jensen
Troels Kornfelt
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0215218A publication Critical patent/BR0215218A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO AQUOSA LìQUIDA, MéTODO PARA A PREPARAçãO DA MESMA, USO DE UMA COMPOSIçãO, E, MéTODOS PARA A INIBIçãO DA COAGULAçãO DO SANGUE EM UM INDIVìDUO, E INIBIçãO DE REAçõES MEDIADAS PELO FATOR DE TECIDO EM UM INDIVìDUO". A invenção apresenta uma composição aquosa líquida, compreendendo (i) um polipeptídeo de fator VII modificado; (ii) um agente adequado para manter o pH na faixa de cerca de 4,0 a cerca de 8,0; (iii) um antioxidante; (iv) um agente escolhido da lista de: um sal de cálcio, um sal de magnésio, ou uma mistura dos mesmos.
BR0215218-5A 2001-12-21 2002-12-20 Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo BR0215218A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101948 2001-12-21
DKPA200101949 2001-12-21
US34688802P 2002-01-07 2002-01-07
US34639902P 2002-01-07 2002-01-07
PCT/DK2002/000894 WO2003055511A1 (en) 2001-12-21 2002-12-20 Liquid composition of modified factor vii polypeptides

Publications (1)

Publication Number Publication Date
BR0215218A true BR0215218A (pt) 2004-11-16

Family

ID=27439852

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215218-5A BR0215218A (pt) 2001-12-21 2002-12-20 Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo

Country Status (12)

Country Link
US (1) US20040043933A1 (pt)
EP (1) EP1458407A1 (pt)
JP (1) JP2005530682A (pt)
CN (1) CN1606452A (pt)
AU (1) AU2002351755A1 (pt)
BR (1) BR0215218A (pt)
CA (1) CA2470313A1 (pt)
HU (1) HUP0402303A2 (pt)
IL (1) IL162618A0 (pt)
PL (1) PL370656A1 (pt)
RU (1) RU2004122430A (pt)
WO (1) WO2003055511A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158615A0 (en) * 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005023308A1 (en) * 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
US20080260858A1 (en) * 2005-02-16 2008-10-23 The Board Of Trustees Of The University Of Illnois Universal Procoagulant
CA2600907C (en) * 2005-03-04 2016-06-28 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
RU2571931C2 (ru) * 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
RS60101B1 (sr) * 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2790213A1 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2763404T3 (es) 2010-08-11 2020-05-28 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
CN104053449B (zh) 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
CN107490696A (zh) * 2017-08-10 2017-12-19 迈克生物股份有限公司 一种视黄醇结合蛋白检测试剂盒及检测方法
CN107490676B (zh) * 2017-08-10 2019-02-12 迈克生物股份有限公司 一种补体c3检测试剂盒及检测方法
CN107490675B (zh) * 2017-08-10 2019-02-12 迈克生物股份有限公司 一种免疫比浊试剂盒及检测方法
CN107356764A (zh) * 2017-08-10 2017-11-17 迈克生物股份有限公司 一种载脂蛋白e检测试剂盒及检测方法
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations

Also Published As

Publication number Publication date
US20040043933A1 (en) 2004-03-04
IL162618A0 (en) 2005-11-20
WO2003055511A1 (en) 2003-07-10
EP1458407A1 (en) 2004-09-22
AU2002351755A1 (en) 2003-07-15
CA2470313A1 (en) 2003-07-10
JP2005530682A (ja) 2005-10-13
RU2004122430A (ru) 2005-04-20
CN1606452A (zh) 2005-04-13
PL370656A1 (en) 2005-05-30
HUP0402303A2 (hu) 2005-01-28

Similar Documents

Publication Publication Date Title
BR0215216A (pt) Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
Zhao et al. The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling
Yuste et al. The contribution of apoptosis-inducing factor, caspase-activated DNase, and inhibitor of caspase-activated DNase to the nuclear phenotype and DNA degradation during apoptosis
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
Bushell et al. Caspase-3 is necessary and sufficient for cleavage of protein synthesis eukaryotic initiation factor 4G during apoptosis
BRPI0408439A (pt) composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0500456A (pt) Dispositivo de colágeno e método para preparar o mesmo
BRPI0518637A2 (pt) agentes para controlar os fluidos biolàgicos e mÉtodos de uso dos mesmos
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
EP1589969A4 (en) 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
BR0317358A (pt) Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
AU2406402A (en) Substituted benzene derivatives or salts thereof
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
BRPI0407709A (pt) heterociclos bicìclicos, composições farmacêuticas contendo esses compostos, seu uso e processos para o preparo dos mesmos
AR035889A1 (es) Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos
Soodvilai et al. Renal organic cation transporters mediated cadmium-induced nephrotoxicity
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DE60104051D1 (de) Anti-Protist Zusammensetzung
Nilsson et al. Presence of neuropeptide Y Y1 receptor mediating vasoconstriction in human cerebral arteries
Takahashi et al. Ultraviolet B irradiation induces apoptosis of keratinocytes by direct activation of Fas antigen
DK0719559T3 (da) Viskøse natriumhyaluronatopløsninger til anvendelse som maskerende væsker i terapeutisk fotokeratektomi under anvendelse af
BR0213486A (pt) Combinações que compreendem um inibidor seletivo de ciclooxigenase-2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]